Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the topical use of systemic drugs for cutaneous disorders and reports a lack of strong evidence from randomized controlled trials, highlighting the need for larger comparative effectiveness studies.

This report describes a 3-year-old boy with a potential new neurocutaneous syndrome characterized by unilateral alopecia, ipsilateral hemimegalencephaly, and intractable seizures.

This article reviews behavioral dermatology, highlighting the importance of integrating physiological, social, and environmental factors in managing dermatologic conditions with behavioral components, but reports no new clinical results.

This article reviews the interconnectedness of the skin and nervous system and discusses various treatment options for psychophysiological skin disorders, reporting no new clinical results.

The meeting showcased rare skin disease cases, highlighting the need for accurate diagnosis and treatment.

This study found that midazolam, unlike clonazepam, increased neurosteroid levels and affected synaptic inhibition and plasticity in rat hippocampal neurons, suggesting unique actions via dual receptor activation.

This report describes five cases where sudden akathisia occurred in female patients with bipolar disorder after a ziprasidone dose reduction, emphasizing potential unexpected side effects of second-generation antipsychotics.

Olanzapine reduces stress-related anxiety in rats when given acutely.

This review discusses the side effects of carbamazepine, valproate, and clonazepam, noting that these are rare with long-term use but more common, transient, and generally mild during early treatment.

This article provides an overview of the indications, interactions, and various potential adverse reactions associated with several drugs, but it reports no specific new results.

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.

This review discusses various psychiatric treatments including antipsychotics, insomnia medication, and mood stabilizers, but reports no new clinical results; the authors comment on existing findings and approvals.

This study found that altering neurosteroid levels during early development in male rats can influence KCC2 levels, underscoring the role of neurosteroids in hippocampal maturation.

Increasing olanzapine caused hair loss in a woman, which stopped after changing medication.

A woman's hair grew back after she stopped taking the Parkinson's disease medication pramipexole.

This study found that spironolactone improved cognitive performance in patients with bipolar disorder experiencing manic episodes, but did not significantly affect manic symptoms, recommending further research with larger sample sizes and longer follow-ups.

Metoprolol and propranolol may cause hair loss.

This study developed a new clustering model to improve detection of drug-induced cognitive disorder risk signals, finding that it identified drugs with moderate risk signals, like Carbidopa/Levodopa, missed by traditional methods, enhancing clinical assessment comprehensiveness.

This case report suggests that Citalopram may cause reversible hair loss in some patients, as evidenced by hair regrowth after discontinuing the drug.

This study found that finasteride reduced impulsivity in a rat model of pramipexole-induced probability discounting, possibly by normalizing D3 receptor expression in the nucleus accumbens.

This article provides regulatory updates, legal briefs, and industry news, reporting no new clinical findings.

Different medications can cause serious side effects in some people.

This study detected insomnia risk signals associated with various medications, primarily nervous system drugs, using the FDA's Adverse Event Reporting System data from 2004 to 2024.

Pramipexole can cause side effects like dizziness, sleepiness, hallucinations, and low blood pressure, and it's important to educate patients and keep doses low.

This source reports that clascoterone cream has been approved in the U.S. for treating acne vulgaris in patients aged 12 and older, suggesting it works by competing with dihydrotestosterone at androgen receptors to mitigate acne's effects.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

This case report describes alopecia associated with escitalopram use, which improved upon switching to duloxetine, and examines existing literature on antidepressant-related hair loss.

This study reported no evidence that clomipramine reduces overgrooming or improves hair regrowth in cats with psychogenic alopecia compared to untreated cats.